The Administrative Core will be responsible for managerial oversight of all Johns Hopkins Prostate Cancer SPORE Program activities. In addition, the Core will help facilitate interactions between Johns Hopkins Prostate Cancer SPORE Program Investigators and Investigators associated with other Prostate Cancer SPORE Programs, and help orchestrate productive responses to the new National Cancer Institute initiatives. The managerial structure of the Johns Hopkins Prostate Cancer SPORE Program, with its Principal Investigator, Co-Principal Investigator, Executive Committee, Internal Oversight Committee, and External Scientific Advisory Board, has been designed to promote translational research by creating a prostate cancer research culture and transcends academic Departments, medical disciplines, and individual research skills, and providing high quality monitoring, evaluation, and oversight of the SPORE portfolio of Research Projects, Core Resources, the Career Development Program, and the Developmental Research Program. The Administrative Core will provide communications, resources, including teleconferencing, travel funds, and administrative staffing for all its managerial activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058236-18
Application #
8379614
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
2014-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
18
Fiscal Year
2012
Total Cost
$117,536
Indirect Cost
$59,214
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Teply, Benjamin A; Wang, Hao; Luber, Brandon et al. (2018) Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. Lancet Oncol 19:76-86
Zennami, Kenji; Choi, Su Mi; Liao, Ross et al. (2018) PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance. Mol Cancer Res :
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Joshu, Corinne E; Peskoe, Sarah B; Heaphy, Christopher M et al. (2018) Current or recent smoking is associated with more variable telomere length in prostate stromal cells and prostate cancer cells. Prostate 78:233-238
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663
Shrestha, Eva; White, James R; Yu, Shu-Han et al. (2018) Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. J Urol 199:161-171
Lu, Yunqi; Hu, Zhongyi; Mangala, Lingegowda S et al. (2018) MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels. Cancer Res 78:64-74
Das, Swadesh K; Pradhan, Anjan K; Bhoopathi, Praveen et al. (2018) The MDA-9/Syntenin/IGF1R/STAT3 Axis Directs Prostate Cancer Invasion. Cancer Res 78:2852-2863
Karnes, R Jeffrey; Choeurng, Voleak; Ross, Ashley E et al. (2018) Validation of a Genomic Risk Classifier to Predict Prostate Cancer-specific Mortality in Men with Adverse Pathologic Features. Eur Urol 73:168-175

Showing the most recent 10 out of 750 publications